Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alnylam Pharmaceuticals, Inc. (ALNY)’s Surge Caps Off a Strong Week in Biotech

Page 1 of 2

Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts. Even the Nasdaq Biotechnology Index can swing wildly with a strong week, the way it did over the past five days, shooting up by nearly 5.5% — more than twice the S&P 500 (INDEXSP:.INX)‘s gains for the week despite the S&P’s run up to record highs.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

What fueled biotech’s big gains this week? Let’s check out three of the top movers in the industry and dig into what you need to know.

Celldex falls, but potential remains

Celldex Therapeutics, Inc. (NASDAQ:CLDX) didn’t help the biotech industry’s cause this week with a 4.4% dip, but the drop wasn’t for a lack of performance recently. It’s hard to pick out stocks that have rewarded investors as Celldex Therapeutics, Inc. (NASDAQ:CLDX) has this year, as shares of the company, which is in the developmental stage as it builds up its phase 3  trial for glioblastoma-fighting Rindopepimut, have jumped an explosive 200% year to date. That’s the kind of booms that a biotech investment get can you.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) didn’t have bad news plague its week, either — on the contrary, this company’s been humming along just fine recently. For a company still early on its life, Celldex has looked strong so far as it develops Rindopepimut and CDX-011, its phase 2 drug candidate to fight a difficult form of breast cancer. This week’s fall seems more about investors looking to pull back on gains more than anything else, but CDX-011 and Rindopepimut both have looked strong in combatting stubborn diseases so far, and this stock has proved that big gains are no problem. In the world of biotech, a 200% year-to-date run-up certainly doesn’t preclude even higher gains if Celldex’s good momentum keeps up.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted a much better week for investors, as the orphan disease-treating company’s shares jumped 18.5% over the past five days. In the biotech world, buyout rumors are hype-worthy events — and Alexion’s right in the center of one, as Big Pharma’s Roche Holding Ltd. (ADR) (OTCBB:RHHBY) is reportedly looking into adding the company to its ranks, according to sources listed by Reuters.

It won’t be a cheap buy for Roche Holding Ltd. (ADR) (OTCBB:RHHBY): Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s already valued at more than $22 billion by its market cap. However, Alexion’s worth the money: Its orphan blood disease-treating Soliris, the company’s only drug on the market, racked up more than $1.1 billion in sales last year, a 45% year-over-year gain that’s only headed higher.

Page 1 of 2
Loading Comments...